A systematic review and pooled analysis was performed to compare stereotactic body radiation therapy (SBRT) and radiofrequency ablation (RFA) in inoperable stage I NSCLC. A comprehensive literature search for published trials from the last 15 years was undertaken. The local tumor control rate (LCR) at 1, 2, 3, and 5 years for RFA was significantly lower than that for SBRT Purpose: To performed a systematic review and pooled analysis to compare clinical outcomes of stereotactic body radiation therapy (SBRT) and radiofrequency ablation (RFA) for the treatment of medically inoperable stage I non-small cell lung cancer. Methods and Materials: A comprehensive literature search for published trials from 2001 to 2012 was undertaken. Pooled analyses were performed to obtain overall survival (OS) and local tumor control rates (LCRs) and adverse events. Regression analysis was conducted considering each study's proportions of stage IA and age. Results: Thirty-one studies on SBRT (2767 patients) and 13 studies on RFA (328 patients) were eligible. The LCR (95% confidence interval) at 1, 2, 3, and 5 years for RFA was 77% (70%-85%), 48% (37%-58%), 55% (47%-62%), and 42% (30%-54%) respectively, which was significantly lower than that for SBRT: 97% (96%-98%), 92% (91%-94%), 88% (86%-90%), and 86% (85%-88%) (P<.001). These differences remained significant after correcting for stage IA and age (P<.001 at 1 year, 2 years, and 3 years; PZ.04 at 5 years). The effect of RFA was not different from that of SBRT on OS (P>.05). The most frequent complication of NotedAn online CME test for this article can be taken at http:// astro.org/MOC.
Introduction
Nearly 25% of patients with early-stage or stage I nonsmall cell lung cancer (NSCLC) are considered medically inoperable (1, 2), with 5-year survival rates of only approximately 15% before the era of stereotactic body radiation therapy (SBRT), which are significantly poorer than for those who receive surgery (2, 3) . Local failure was the primary cause of failure (4, 5) . Stereotactic body radiation therapy, which is also referred to as stereotactic ablative radiation therapy, has emerged as an important treatment option for inoperable stage I NSCLC over the last 10 years. This radiation technology allows accurate delivery of a very high dose to the tumor, while sparing normal adjacent tissue. In prospective and large retrospective multicenter studies, when an adequate dose (biologically equivalent dose [BED] !100 Gy) is used, high local control rates (LCRs) of more than 90% have been reported, as well as promising overall survival (OS) advantages and good tolerance compared with conventional radiation therapy (6, 7, 8) . The recently published results from the Radiation Therapy Oncology Group 0236 trial demonstrated a 3-year actuarial LCR of 98%, while altogether avoiding severe toxicity in more than 75% of treated patients (8) . With this and other evidence, SBRT is the current standard of care for medically inoperable stage I NSCLC.
Radiofrequency ablation (RFA) is another promising nonsurgical therapeutic alternative for small, peripheral tumors. It can be performed percutaneously, under conscious sedation and image guidance, and as an outpatient procedure or with a short hospital stay. The use of RFA to treat lung malignancies in human was first reported in 2000 (9) . The largest prospective, multicenter trial of RFA for lung tumors was the RAPTURE study published in 2008, which enrolled 106 inoperable patients with 183 lung tumors, including 33 primary NSCLC patients (10) . A 75% 2-year OS has been shown in patients with stage I NSCLC (nZ13), and a confirmed complete response lasting at least 1 year was 88%. Radiofrequency ablation treatment was well tolerated. Major complications were symptomatic pneumothorax needing drainage (nZ27) and pleural effusion needing drainage (nZ4). Minor complications were pneumothorax (nZ28) or pleural effusion (nZ11) not needing treatment and self-limiting intrapulmonary hemorrhage (nZ3). However, the majority of RFA studies in early-stage NSCLC are small case series, and the reported LCRs ranged greatly from 58% to 95% (11, 12, 13, 14) .
At present no direct comparison of clinical outcomes between RFA and SBRT has been published. Furthermore, it is often challenging for a tumor board to decide between RFA and SBRT, because many patients are candidates for both treatments, and it is unknown which treatment would provide superior outcome. In addition, outcome data from randomized studies are lacking, and no such prospective trial is ongoing. Therefore, we performed this systemic review and pooled analysis to provide a comparison between RFA and SBRT, for treatment of medically inoperable stage I NSCLC, with a focus on LCR, OS, and treatment-related toxicities.
Methods and Materials
A comprehensive literature search was performed using MEDLINE, Embase, and the Cochrane Library from 2001 to 2012. Specific search terms used included the following: radiofrequency ablation, thermal ablation, stereotactic radiation therapy, stereotactic radiation therapy, stereotactic ablative radiation therapy, non-small cell lung carcinoma, and NSCLC. Reference lists of obtained articles were searched as well.
Inclusion and exclusion criteria
The eligibility criteria included were as follows: (1) stage I NSCLC diagnosis; (2) medically inoperability; and (3) reporting on the outcome of patients after RFA or SBRT. Outcome data included LCRs at 1, 2, 3, and 5 years, and OS rates at 1, 2, 3, and 5 years. Local control was assessed by follow-up radiologic image and defined as no tumor recurrence/progression in the primary site. Procedurerelated morbidity and mortality were also analyzed. Studies about RFA followed by immediate resection or radiation therapy, or SBRT with BED <100 Gy, fraction dose <8 Gy, or using more than 5 fractions, or with fewer than 5 patients in the RFA group and 30 patients in the SBRT group were excluded. We limited the SBRT to 5 fractions or less to make the patient population more comparable to that of RFA (ie, peripheral location). Case reports, review articles, unpublished data, and publications in languages other than English were also excluded from further analysis. Studies and/or subgroups were included if reporting sufficient data on LCR, OS, and treatment-related morbidity. In case of potential duplication or overlapping studies, only the largest and most complete data set was included, according to published information.
Data extraction
One investigator (N.B.) identified the articles for this topic. Two investigators (N.B., X.Z.) extracted the data on study characteristics, study population, technical details, and outcome measurements using a standardized Excel file and reached consensus on all items. No attempt was made to get missing data from the authors. The BED 10 was calculated according to the following linear-quadratic equation:
, where a/bZ10 and n and d represent the number of fractions and the dose per fraction, respectively. The 1-, 2-, 3-, and 5-year LCR and OS were extracted from each study if available, as well as the occurrence of adverse events. In studies in which survival rates were not explicitly stated but Kaplan-Meier survival curves were provided, survival data were extracted from survival curves.
In stage I NSCLC the occurrence of severe adverse events (Common Terminology Criteria for Adverse Events grade 3-5) was infrequent for all treatment modalities. The majority of SBRT studies reported zero adverse events; therefore, we added up the adverse events occurring for each treatment modality instead of pooling the estimates using a regression. Proportions and 95% confidence intervals (CIs) were calculated using a binomial distribution.
Data analysis
The primary endpoint of this study was LCR at 3 years. Secondary endpoints were OS and treatment-related thoracic toxicity.
A pooled analysis was used to determine weighted summary statistics for each of the treatments. The results were presented as pooled proportions of patients surviving (or local progression-free surviving) 1, 2, 3, and 5 years from diagnosis, with 95% CIs. Because standard errors for the surviving proportions of patients were not consistently reported, we inferred them from the reported median followup times using the parametric bootstrap (15) . Application of the parametric bootstrap to survival data requires models for both the survival and censoring processes. To obtain a model for the population survival process, for each study, a model was fit to the reported survival times (at 1, 2, 3, and 5 years as reported). For studies with only 1 reported follow-up time, a 1-parameter exponential model was used. For studies with 2 or more reported follow-up times, a 2-parameter Weibull model was used. The right tail of the population survival curve was fit to the reported surviving patient fractions using least squares. The censoring process was modeled as an exponential distribution, with median equal to the reported median follow-up time. Simulation was then used to estimate the standard errors for estimating the surviving patient fractions, based on data sets of the reported sample size, from the estimated survival and censoring processes. Because differences between the characteristics of the study populations may influence the effectiveness of different treatment modalities, regression analysis was performed considering each study's proportions of stage IA and patients' age. All the analyses were done using R language (www.r-project.org).
Results

Literature search
The literature search performed in July 2012 yielded 1270 articles (Fig. 1) . Among them, 478 articles were found to be pertinent. Three hundred six studies were excluded because they failed to meet the eligibility criteria on the basis of the screening of the titles and abstracts. Of the remaining 172 references, the full texts were retrieved and the data analyzed. One additional reference on RFA was retrieved through manual searches of the reference lists. Ultimately, 44 articles were found to report data of interest and fulfilled the inclusion criteria of the present study: 13 studies including 328 patients on RFA (10-14, 16-23) and 31 studies including 2767 patients on SBRT (6-8, 24-51). There were no randomized, controlled trials or nonrandomized studies directly comparing the differences between RFA and SBRT. All eligible studies were single-arm observational studies or subgroups of comparative studies. Tables 1 and 2 summarize the main characteristics of these studies.
Local control for medically inoperable stage I NSCLC
Forty studies reported LCRs ( Fig. 2 and Table 3 ). In the RFA group, 5 studies (142 patients) reported 1-year LCR, 4 studies (113 patients) reported 2-year LCR, 6 studies (248 patients) reported 3-year LCR, and 4 studies (106 patients) reported 5-year LCR. In the SBRT group, 20 studies (2107 patients) reported 1-year LCR, 22 studies (2137 patients) reported 2-year LCR, 21 studies (2151 patients) reported 3-year LCR, and 6 studies (1192 patients) reported 5-year LCR. The results of the fixed-effect pooled analysis on LCR are presented in Table 3 . The 1-, 2-, 3-, and 5-year LCR estimates and their 95% CIs were 77% (70%-85%), 48% (37%-58%), 55% (47%-62%), and 42% (30%-54%) for RFA and 97% (96%-98%), 92% (91%-94%), 88% (86%-90%), and 86% (85%-88%) for SBRT, respectively. The uncorrected pooled 1-, 2-, 3-, 5-year LCRs for RFA were all significantly lower than those for SBRT (all P<.001).
Overall survival for medically inoperable stage I NSCLC
All studies reported OS ( Fig. 3 and Table E1 ; available online at www.redjournal.org). In the RFA group, 12 studies (313 patients) reported 1-year OS, 12 studies (295 patients) reported 2-year OS, 9 studies (240 patients) reported 3-year OS, and 8 studies (216 patients) reported 5-year OS. In the SBRT group, 27 studies (2467 patients) reported 1-year OS, 26 studies (2377 patients) reported 2-year OS, 21 studies (2003 patients) reported 3-year OS, and 10 studies (1503 patients) reported 5-year OS. The results of the fixed-effect pooled analysis on OS are presented in Table E1 (available online at www.redjournal.org). The 1-, 2-, 3-, and 5-year OS estimates and their 95% CIs were 85% (80%-89%), 67% (61%-74%), 53% (45%-61%), and 32% (22%-43%) for RFA and 85% (84%-87%), 68% (66%-70%), 56% (53%-59%), and 40% (36%-45%) for SBRT. Neither treatment had significantly different uncorrected 1-, 2-, 3-, and 5-year OS (all P>.05).
Comparison between RFA and SBRT: Regression analysis
Regression analysis was conducted to adjust for the different influence of clinical factors on effectiveness of different treatment modalities. After adjusting for age and percentage of stage IA, the corrected pooled 1-, 2-, 3-, and 5-year LCRs for SBRT were significantly higher than those Abbreviations: F/U Z follow-up period; IA/I Z percentage of patients with stage IA disease; NA Z not reported or not specified; P Z prospective; Path. Z percentage of disease with pathologic confirmation; R Z retrospective. Abbreviations: BED 10 Z biological equivalent dose with a/b Z 10; Fx Z fractions. Other abbreviations as in Table 1 . for RFA (P<.05, respectively; Table 3 ). Radiofrequency ablation and SBRT did not have statistically significantly different 1-, 2-, 3-, and 5-year OS (Table E1 ; available online at www.redjournal.org).
Occurrence of adverse events
The total occurrence of each adverse event per treatment modality, as well as the number of patients at risk, is listed in Table E2 (available online at www.redjournal.org). Overall, both RFA and SBRT studies reported limited severe adverse events. The most frequent complication of RFA was pneumothorax (grade !1), which was reported in 31% (95% CI 19%-43%) of patients. Severe pneumothorax that required intervention (grade !3) occurred in 13% (95% CI 0%-27%) of patients. The most frequent grade 3 or greater toxicity for SBRT was radiation pneumonitis, occurring in 2% of patients (95% CI 1%-4%). The second 
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most frequent toxicity was rib fracture, occurring in 2% of patients (95% CI 1%-3%). The incidence of severe (grade !3) acute esophageal toxicity, however, was uncommon. Several studies also reported cases of grade 3/4 adverse events, but because they did not specify the types of adverse events, these were not incorporated into the count.
Discussion
To our knowledge, this is the first systemic review and pooled analysis to compare the efficacy and morbidity of RFA and SBRT for medically inoperable early-stage NSCLC. A total of 44 studies, 13 for RFA and 31 for SBRT, were used in the comparison. The 1-, 2-, 3-, and 5-year LCRs, corrected for differences in each study's proportions of stage IA and age, were significantly higher after SBRT than those after RFA treatment. The OS rates for RFA and SBRT were comparable. Both SBRT and RFA reported limited risk of severe toxicity. A number of literature reviews that separately addressed the effectiveness of SBRT and RFA were published recently (52, 53, 54, 55, 56) . However no actual pooled analysis has been published to date. Recently Bial et al (57) performed an English literature review to compare RFA with SBRT in patients with early-stage medically inoperable NSCLC. A total of 16 studies (9 studies for RFA and 7 studies for SBRT) were used to answer this question. They found that the OS at 1 year (68.2%-95% vs 81%-85.7%) and 3 years (36%-87.5% vs 42.7%-56%) was similar between patients treated with RFA and stereotactic ablative radiation therapy, whereas 5-year OS was higher for SBRT (47%) than for RFA (20.1%-27%). Local progression rates were lower in patients treated with SBRT (3.5%-14.5% vs 23.7%-43%). These results were different from the pooled estimates presented in the current study, showing better local control without significant difference in 5-year survival. The difference might be explained by 2 main factors. First, Bial et al (57) did not use a statistical approach to analyze all the data. Second, our analysis included more studies, and especially recently published studies. We used 8 studies for RFA and 10 studies for SBRT that reported 5-year OS results, whereas only 2 RFA studies and 1 SBRT study were included in Bial's review.
A cost-effectiveness analysis published by Sher et al (58) compared conventional RT, SBRT, and RFA for medically inoperable stage I NSCLC. They developed a Markov model to describe health states of 65-year-old men with medically inoperable NSCLC after treatment with 3-dimensional conformal radiation therapy (3D-CRT), SBRT, and RFA. They found that SBRT is the most cost-effective treatment for medically inoperable stage I NSCLC. The incremental costeffectiveness ratio for SBRT over 3D-CRT was $6000 per quality-adjusted life-year, and the incremental costeffectiveness ratio for SBRT over RFA was $14,100 per quality-adjusted life-year. However, these results were based on a wide range of assumptions, including the efficacy of each treatment modality. For example, the local recurrence rates they used for RFA treatment was only derived from 1 retrospective study, published by Simon et al (21) . The 3-year LCR for RFA in that study was only 43%, which was significantly lower than pooled result (55%, 95% CI 47%-62%) from this study. The possible explanation of this difference is that the study by Simon et al included not only primary early-stage NSCLC but also metastatic lung cancer (more than 40%). Because the local recurrence risk of RFA is one key variable that could change the outcome of costeffectiveness analysis, our pooled estimate results on SBRT and RFA might be helpful to improve the predictive accuracy of their model.
A strong correlation between the size of the targeted tumors and the RFA treatment results has been reported. Higher rates of relapse were noted in tumors larger than 2 to 4 cm. Simon et al (21) reported on 75 patients with stage I NSCLC who were treated with RFA and followed for 5 years; the 5-year progression-free survival was significantly higher in tumors <3 cm (47%) compared with larger tumors (25%). Okuma et al (13) identified that the significant risk factor for local progression after RFA was tumor size !2 cm (hazard ratio 1.5, 95% CI 1.2-2.0), whereas Huang et al (59) indicated that significant difference in the risk of local progression was found in tumors >4 cm. A recent study including 55 ablations in 45 patients with stage I NSCLC reported more local failures in tumors >3 cm (80%), compared with lesions <3 cm (29%) (19) . All this evidence suggested that the difference in the percentage of small tumors (<3 cm, stage IA patients) between the study populations might significantly influence the outcome. Therefore, in the present study we performed a regression analysis and found that after correcting for differences in tumor size (the percentage of stage IA patients), the local tumor control rates at 1, 2, 3, and 5 years were still significantly better for SBRT compared with RFA (P<.001 at 1 year, 2 years, and 3 years; PZ.04 at 5 years). Although the LCR was significantly higher in patients treated with SBRT, the pooled estimates of OS between SBRT and RFA were similar. These results were consistent with those of a recent prospective study (60) that included 116 patients treated with sublobar resection (nZ42), RFA (nZ25), or radiation therapy (nZ49). After adjusting for age and tumor size, a significant difference in the partial response (PR) PR rate was observed, but no significant differences in OS. The comparison of long-term survival outcomes assessing alternate therapies for high-risk patients is challenging because the comorbidity and mortality rates are high. Evidence showed that even without any cancer, the median 5-year OS for patients with severe chronic obstructive pulmonary disease was only approximately 40% (61) . As many as one-third of medically inoperable patients with NSCLC would die from comorbid conditions rather than cancer (55) . It has been suggested that for medically inoperable patients with NSCLC, local tumor control and relapse-free survival might be more valid endpoints than OS (54) . Although our study demonstrated that the local tumor control was significantly better for SBRT than for RFA treatment, there are certainly a number of limitations. First, this is a systemic review and pooled analysis based on observational studies. When combining observational studies, heterogeneity of populations, design, and outcome are expected, and these differences may influence the pooled estimates. However, despite these challenges, when no randomized, controlled trials or retrospective studies directly comparing RFA and SBRT are available, a systemic review and pooled analysis of observational studies might be a valid method for assessing efficacy and effectiveness, and could provide useful evidence to inform the decision whether more evidence is needed. Moreover, a regression analysis could correct for some potential differences between study populations or designs. Second, most RFA studies were small case series with relatively short follow-up, which led to wide variance of LCRs and OS estimated by formula. Four RFA studies were newly published (60, 62-64) while we were preparing this article. A local progression rate of more than 20%, 1-year LCR of 68.9%, and 2-year LCR of 59.8% were reported, which were similar to our pooled results. Third, definitions of local progression are not always consistent across the published reports. The wide range (3-50%) of local tumor progression after earlier RFA studies may be partially explained by these variations. Last, we did not look at trials presented only in their abstract form or at unpublished studies, nor at studies without separate data for early-stage NSCLC patients. This emphasizes the importance that authors should fully document the characteristics of the study populations in their articles.
In conclusion, this systemic review and pooled analysis demonstrated that SBRT provided superior 1-, 2-, 3-, and 5-year local tumor control over RFA, even when corrected for patients' age and tumor size 3 cm. Therefore, at present, SBRT is still the most effective local treatment for inoperable stage I NSCLC patients, and RFA should be offered only if patients are not candidates for SBRT. However, caution should be taken owing to the relatively limited number of RFA trials and short follow-up time. More studies with larger sample sizes for RFA treatment are needed.
